Copyright
©The Author(s) 2015.
World J Hepatol. Sep 8, 2015; 7(19): 2220-2228
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220
Figure 4 Comparison of cumulative hepatocellular carcinoma incidence after interferon therapy between the groups of sustained virological response patients with different alpha-fetoprotein values with propensity score matching.
Age, sex, platelet count, and alanine aminotransferase were matched for sustained virological response patients showing AFP values ≥ 5 ng/mL or < 5 ng/mL before interferon therapy by propensity score. Cumulative HCC incidence after interferon therapy was compared in groups of patients with different AFP values using the Kaplan-Meier method. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.
- Citation: Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228
- URL: https://www.wjgnet.com/1948-5182/full/v7/i19/2220.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i19.2220